- Home
- AGIO vs TDOC Comparison
AGIO vs TDOC Comparison
Compare AGIO & TDOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- TDOC
- Stock Information
- Founded
- AGIO 2007
- TDOC 2002
- Country
- AGIO United States
- TDOC United States
- Employees
- AGIO N/A
- TDOC N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- TDOC Medical/Nursing Services
- Sector
- AGIO Health Care
- TDOC Health Care
- Exchange
- AGIO Nasdaq
- TDOC Nasdaq
- Market Cap
- AGIO 1.4B
- TDOC 1.2B
- IPO Year
- AGIO 2013
- TDOC 2015
- Fundamental
- Price
- AGIO $39.05
- TDOC $8.35
- Analyst Decision
- AGIO Buy
- TDOC Buy
- Analyst Count
- AGIO 6
- TDOC 19
- Target Price
- AGIO $58.60
- TDOC $9.65
- AVG Volume (30 Days)
- AGIO 602.7K
- TDOC 8.8M
- Earning Date
- AGIO 07-31-2025
- TDOC 07-30-2025
- Dividend Yield
- AGIO N/A
- TDOC N/A
- EPS Growth
- AGIO N/A
- TDOC N/A
- EPS
- AGIO 11.45
- TDOC N/A
- Revenue
- AGIO $37,035,000.00
- TDOC $2,552,812,000.00
- Revenue This Year
- AGIO $22.30
- TDOC N/A
- Revenue Next Year
- AGIO $219.19
- TDOC $1.32
- P/E Ratio
- AGIO $3.45
- TDOC N/A
- Revenue Growth
- AGIO 25.96
- TDOC N/A
- 52 Week Low
- AGIO $23.42
- TDOC $6.35
- 52 Week High
- AGIO $62.58
- TDOC $15.21
- Technical
- Relative Strength Index (RSI)
- AGIO 70.00
- TDOC 56.35
- Support Level
- AGIO $34.60
- TDOC $7.94
- Resistance Level
- AGIO $40.06
- TDOC $9.10
- Average True Range (ATR)
- AGIO 1.49
- TDOC 0.52
- MACD
- AGIO 0.43
- TDOC 0.05
- Stochastic Oscillator
- AGIO 86.59
- TDOC 69.06
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About TDOC Teladoc Health Inc.
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.